Dr. Tamara Suzanne Hudson, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 121 Calle Del Presidente, Bernalillo, NM 87004 Phone: 505-867-2324 Fax: 505-771-3431 |
Kathryn Mcclain, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2 Dove Rd, Bernalillo, NM 87004 Phone: 505-867-2497 |
Rachel Davis Rankin, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 121 Calle Del Presidente, Bernalillo, NM 87004 Phone: 505-867-2324 Fax: 505-867-3511 |
Dr. Cathleen Durell, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 203 Sandia Day School Road, Bernalillo, NM 87004 Phone: 505-867-4696 Fax: 505-867-4997 |
Gayle Chacon, Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 481 Sandia Loop, Sandia Pueblo Clinic, Bernalillo, NM 87004 Phone: 505-867-4487 |
Dr. Martin Jon Kileen, M.D.,M.P.H. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: Santa Ana Clinic, O2-c Dove Rd, Bernalillo, NM 87004 Phone: 505-867-2497 Fax: 505-867-1526 |
Dr. Dianna Lynne Fury, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 203 Sandia Day School Road, Bernalillo, NM 87004 Phone: 505-867-4696 Fax: 505-867-4997 |
Dr. Alan Mark Firestone, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 121 Calle Del Presidente, Bernalillo, NM 87004 Phone: 505-867-2324 Fax: 505-867-3511 |
News Archive
Helping kidney dialysis patients have healthier treatment sessions and longer lives is the goal of a new $6.7 million project at the University of Michigan.
AbbVie today announced results from its multi-country ALIGN study, which shows that across six chronic immune-mediated inflammatory diseases (IMIDs), adherence to treatment was generally higher in patients being treated with TNF inhibitors compared to patients treated with conventional therapy.
Rather like a physical fingerprint, the gut microbial pattern can be used to identify certain vulnerabilities in patients who are undergoing radiation therapy for prostate or gynecologic cancer, predicting which of them are most likely to suffer damage to the intestine.
Cellectricon AB and Censo Biotechnologies Ltdare announcing the introduction of a joint technology access program for a fully humanized phenotypic screening platform targeting preclinical neuroscience and chronic pain research.
› Verified 4 days ago